Ranok Therapeutics Announces Commencement of Patient Dosing in Phase 1/2 Clinical Trial of RNK05047, a First-in-Class CHAMP™ Protein Degrader Targeting BRD4


BOSTON & HANGZHOU, CHINA–(BUSINESS WIRE)–Ranok Therapeutics, a clinical-stage biopharmaceutical company developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today announced the launch of the patient assay in the United States for a phase 1/2 study on RNK05047. The trial, titled CHAMP-1, will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RNK05047 in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL). Ranok anticipates preliminary data from the study in the second half of 2023.

“RNK05047 is Ranok’s first therapy based on our proprietary CHAMP™ technology, as well as the pharmaceutical industry’s first BRD4 protein degrader to enter clinical trials,” said Weiwen Ying, Ph.D., Founder and CEO. by Ranok. “RNK05047 is designed to selectively degrade the BRD4 protein preferentially in tumors, thereby improving safety and efficacy, which differentiates it from other investigational therapies such as non-selective BET inhibitors.”

“The BET bromodomain BRD4 transcription factor is a master regulator of oncogenes implicated in various types of cancer,” said Manuel Hidalgo Medina, MD, Ph.D., chief of the division of hematology and medical oncology at Weill Cornell. Medicine and New York-Presbyterian/Weill Cornell Medical Center, associate director of clinical services at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and site principal investigator in the trial. “We are excited to participate in this trial and hope that RNK05047 will provide a new therapeutic option to benefit patients. »

Additional information about this clinical trial (NCT05487170) is available at www.clinicaltrials.gov.

About Ranok’s CHAMP™ Platform

Ranok’s proprietary CHAPERONE-MEDIATED PROTEIN DEGRADATION/DEGRADER (CHAMP™) platform and Chaperone-Tether Library™ are based on our founders’ extensive background in protein homeostasis research. CHAMP™ technology takes advantage of the cellular chaperone network, which regulates protein folding and stability, which sets it apart from other targeted protein degradation approaches. CHAMP™ has a number of unique advantages, such as the avoidance of drug resistance mechanisms, and is designed to improve safety and efficacy through the selective targeting of diseased tissues.

About RNK05047

RNK05047 is a first-in-class tumor and BRD4-selective protein degrader that was discovered and developed using Ranok’s proprietary approach for targeted protein degradation, CHAMP™. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is implicated in various types of cancer. CHAMP-1 is a Phase 1/2 trial of RNK05047 currently underway in the United States that will evaluate its safety, tolerability, and pharmacokinetics, and also includes measurements of antitumor activity and pharmacodynamic readings as endpoints. secondary. Preliminary data are expected from the trial in the second half of 2023.

About Ranok Therapeutics

Ranok is a privately held biopharmaceutical company pioneering CHAMP™, an innovative approach to targeted protein degradation for the discovery and development of novel therapies. Our R&D team brings deep knowledge of biology and expertise in chemistry to rapidly identify and advance CHAMP™ degraders for a variety of important disease targets, with the goal of creating transformative medicines that benefit patients around the world suffering from cancer and other serious illnesses. For more information, please visit the Company’s website at www.ranoktherapeutics.com or follow us on Twitter (@RanokTx) and LinkedIn.


Comments are closed.